benzoxazoles has been researched along with Acute Myelogenous Leukemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, J; Liu, H; Lu, S; Lu, T; Wang, Y; Yang, W; Zhang, J; Zhi, Y | 1 |
| Aust, MM; Dumur, CI; Ferreira-Gonzalez, A; Grant, S; Hawkins, E; Kmieciak, M; Parker, RE; Rahmani, M; Reshko, LB; Rizzo, KA; Ross, M | 1 |
| Bertoli, S; Boutzen, H; David, L; Delabesse, E; Demur, C; Didier, C; Dozier, C; Fernandez-Vidal, A; Galcera, MO; Hospital, MA; Larrue, C; Manenti, S; Mansat-De Mas, V; Récher, C; Saland, E; Sarry, JE; Tamburini, J; Vergez, F; Yuan, L | 1 |
| Bhatt, L; Chang, CJ; Cotter, TG; Dickinson, BC; Gough, DR; Naughton, R; Stanicka, J; Woolley, JF | 1 |
4 other study(ies) available for benzoxazoles and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Discovery of benzo[d]oxazole derivatives as the potent type-I FLT3-ITD inhibitors.
Topics: Benzoxazoles; Cell Line, Tumor; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Dynamics Simulation; Structure-Activity Relationship | 2020 |
Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
Topics: Animals; bcl-X Protein; Benzoxazoles; Biphenyl Compounds; Down-Regulation; Enzyme Activation; Female; Humans; Leukemia, Myeloid, Acute; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred NOD; Mice, SCID; Multiprotein Complexes; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Nucleophosmin; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; U937 Cells; Xenograft Model Antitumor Assays | 2015 |
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Benzoxazoles; cdc25 Phosphatases; Cell Cycle Checkpoints; Cell Death; Cell Differentiation; Cell Proliferation; Child; Coculture Techniques; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; RNA Interference; RNA, Messenger; Signal Transduction; STAT5 Transcription Factor; Tandem Repeat Sequences; Time Factors; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 2015 |
H2O2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling.
Topics: Benzoxazoles; Cell Line, Tumor; Endoplasmic Reticulum; Fluorescent Dyes; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Hydrogen Peroxide; Imidazoles; Leukemia, Myeloid, Acute; Mitochondria; Mutation; NADPH Oxidases; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-pim-1; Pyrroles; RNA, Small Interfering; Signal Transduction; STAT5 Transcription Factor; Staurosporine; Triazoles | 2012 |